[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368517-105":59,"doc-detail-368517-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","an-agrinyaptaz-rigidity-sensing-module-drives-egfr-addicted-lung-tumorigenesis-research-article","An Agrin–YAP/TAZ Rigidity Sensing Module Drives EGFR-Addicted Lung Tumorigenesis - Research Article","","Epidermal growth factor receptor (EGFR) is central to multiple cancers, yet how it senses extracellular matrix (ECM) rigidity in lung adenocarcinoma remains unclear. This study shows EGFR controls tumorigenic agrin expression across lung cancer cell lines, EGFR-driven genetically engineered mouse models, and human specimens. Agrin increases substrate stiffness-dependent oncogenic features and mechanoactivates EGFR via EGF-dependent and independent pathways, promoting cancer cell–ECM adhesion and bulk rigidity sensing. A feed-forward agrin–EGFR rigidity response to YAP–TEAD mechanosensing is required for tumorigenesis, suggesting combined EGFR–YAP/TEAD inhibition as a therapeutic strategy for EGFR-addicted lung cancers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/an-agrinyaptaz-rigidity-sensing-module-drives-egfr-addicted-lung-tumorigenesis-research-article/368517/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/an-agrinyaptaz-rigidity-sensing-module-drives-egfr-addicted-lung-tumorigenesis-research-article/368517.png","ImageObject",300,407,{"name":92,"@type":93},"Riley West","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does EGFR play in sensing extracellular matrix (ECM) rigidity in lung cancer?","Question",{"text":112,"@type":113},"EGFR is shown to dictate tumorigenic agrin expression and to mechanoactivate through EGF-dependent and independent modes, enabling cancer cells to respond to ECM stiffness.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does agrin influence EGFR activity and tumor cell behaviors?",{"text":117,"@type":113},"Agrin confers substrate-stiffness-dependent oncogenic attributes and promotes localized cancer cell–ECM adherence and broader rigidity sensing by fostering integrin-associated interactions that activate EGFR.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is the agrin–EGFR rigidity response to YAP–TEAD mechanosensing important?",{"text":121,"@type":113},"A feed-forward loop linking agrin–EGFR rigidity response to YAP–TEAD mechanosensing is essential for tumorigenesis, indicating that disrupting this pathway can reduce disease progression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368517,1790379681,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523885074,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","RESEARCH ARTICLE  \n[www.advancedscience.com](www.advancedscience.com)  \nAn Agrin–YAP/TAZ Rigidity Sensing Module Drives EGFR-Addicted Lung Tumorigenesis  \nReza Bayat Mokhtari, Divyaleka Sampath, Paige Eversole, Melissa Ong Yu Lin, Dmitriy A. Bosykh, Gandhi T.K. Boopathy, Aravind Sivakumar, Cheng-Chun Wang, Ramesh Kumar, Joe Yeong Poh Sheng, Ellen Karasik, Barbara A. Foster, Han Yu, Xiang Ling, Wenjie Wu, Fengzhi Li, Zoë Weaver Ohler, Christine F. Brainson, David W. Goodrich, Wanjin Hong,* and Sayan Chakraborty*  \nDespite epidermal growth factor receptor (EGFR) is a pivotal oncogene for several cancers, including lung adenocarcinoma (LUAD), how it senses extracellular matrix (ECM) rigidity remain elusive in the context of the increasing role of tissue rigidity on various hallmarks of cancer development. Here it is shown that EGFR dictates tumorigenic agrin expression in lung cancer cell lines, genetically engineered EGFR-driven mouse models, and human specimens. Agrin expression confers substrate stiﬀness-dependent oncogenic attributes to EGFR-reliant cancer cells. Mechanistically, agrin mechanoactivates EGFR through epidermal growth factor (EGF)-dependent and independent modes, thereby sensitizing its activity toward localized cancer cell-ECM adherence and bulk rigidity by fostering interactions withintegrin 􀀂1. Notably, a feed-forward loop linking agrin–EGFR rigidity response to YAP–TEAD mechanosensing is essential for tumorigenesis. Together, the combined inhibition of EGFR–YAP/TEAD may oﬀer a strategy to reduce lung tumorigenesis by disrupting agrin-EGFR mechanotransduction, uncovering a therapeutic vulnerability for EGFR-addicted lung cancers.  \n1. Introduction  \nThe receptor tyrosine kinase (RTK) superfamily of cell-surface receptors mediate cell signaling through extracellular growth factors within the tumor microenvironment (TME).[1] As a member ofthe ErbB family of RTKs, the EGFR is frequently ampliﬁed and mutated in lung adenocarcinoma (LUAD), a prevalent non-small cell lung cancer (NSCLC) subtype. [2] EGFR ampliﬁcations or mutations includingthe in frame exon 19 deletion (Ex19Del) and exon 21 Leu858Arg point mutation (L858R) impact patient prognosis[3,4] In recent years, monumental progress has been achieved on EGFR targeting strategies, as exempliﬁed by the smallmolecule inhibitors geﬁtinib and erlotinib, afatinib, and osimertinib, which revolutionized treatments for patients with advanced NSCLC harboring EGFR mutations, including the T790 M drug resistant mutation. [5]  \nR. B. Mokhtari, P. Eversole, D. A. Bosykh, E. Karasik, B. A. Foster, X. Ling,  \nW. Wu, F. Li, D. W. Goodrich, S. Chakraborty Department of Pharmacology and Therapeutics Roswell Park Comprehensive Cancer Center  \n265 Elm and Carlton Streets, Buﬀalo, NY 14263, USA  \nE-mail: [Sayan.Chakraborty@RoswellPark.org](Sayan.Chakraborty@RoswellPark.org)  \nD. Sampath, M. O. Yu Lin, G. T. Boopathy, A. Sivakumar, C.-C. Wang,  \nR. Kumar, J. Y. P. Sheng, W. Hong Institute of Molecular and Cell Biology  \n61 Biopolis Drive Proteos, Singapore 138673, Singapore [E-mail:](E-mail: mcbhwj@imcb.a-star.edu.sg)[ mcbhwj@imcb.a-star.edu.sg](E-mail: mcbhwj@imcb.a-star.edu.sg)  \nThe ORCID identiﬁcation number(s) for the author(s) of this article  \ncan be found under [https://doi.org/10.1002/advs.202413443](https://doi.org/10.1002/advs.202413443)[ ](https://doi.org/10.1002/advs.202413443)© 2025 The Author(s). Advanced Science published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nDOI: 10.1002/advs.202413443  \nH. Yu  \nDepartment of Biostatistics  \nRoswell Park Comprehensive Cancer Center Buﬀalo, NY 14263, USA  \nZ. W. Ohler  \nCenter for Advanced Preclinical Research Frederick National Laboratory for Cancer Research National Cancer Institute  \nNIH  \nBethesda, MD 20892-1088, USA  \nC. F. Brainson  \nDepartment ","cbCaitkCITKkedu9","https://ap.wps.com/l/cbCaitkCITKkedu9","pdf",6395134,21,"English","# Introduction\n## EGFR targeting and the role of ECM rigidity\n## Agrin as a mechanosignaling ECM component\n# Results and mechanistic model\n## Agrin expression driven by EGFR\n## EGFR mechanoactivation through EGF-dependent and independent modes\n## Requirement of agrin–EGFR to YAP–TEAD mechanosensing loop\n# Therapeutic implications\n## Combined EGFR–YAP/TEAD inhibition for lung cancer treatment","[{\"question\":\"What role does EGFR play in sensing extracellular matrix (ECM) rigidity in lung cancer?\",\"answer\":\"EGFR is shown to dictate tumorigenic agrin expression and to mechanoactivate through EGF-dependent and independent modes, enabling cancer cells to respond to ECM stiffness.\"},{\"question\":\"How does agrin influence EGFR activity and tumor cell behaviors?\",\"answer\":\"Agrin confers substrate-stiffness-dependent oncogenic attributes and promotes localized cancer cell–ECM adherence and broader rigidity sensing by fostering integrin-associated interactions that activate EGFR.\"},{\"question\":\"Why is the agrin–EGFR rigidity response to YAP–TEAD mechanosensing important?\",\"answer\":\"A feed-forward loop linking agrin–EGFR rigidity response to YAP–TEAD mechanosensing is essential for tumorigenesis, indicating that disrupting this pathway can reduce disease progression.\"}]","An Agrin–YAP/TAZ Rigidity Sensing Module Drives EGFR-Addicted Lung Tumorigenesis - Research Article | PDF",1790177307,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0da574c05abdc2bd16c6037281bed01f.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6bd56513452711546ffb6a35154db38d.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0502dc2a1125faeabc54037bbdc2fea.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4e7e93306205111fe6180ba01196d18.webp",980,1287]